Latest News
Conference Coverage
Eculizumab cuts relapse risk in NMO spectrum disorder
PHILADELPHIA – Nearly 98% of patients with this autoimmune inflammatory CNS disorder were relapse-free at 48 weeks in the randomized phase 3...
Feature
Employed physicians now outnumber independent doctors
A majority of doctors still work in small practices, although that number is falling.
Conference Coverage
Single-center study outlines stroke risk, DOAC type in nonvalvular AFib patients
PHILADELPHIA –Rivaroxaban was more often than other DOACs associated with events in nonvalvular atrial fibrillation patients, based on a small...
Conference Coverage
Immunotherapy induces improvements in PML
PHILADELPHIA – Donor-derived T cells seen as having “potential to be one of the first effective treatments for PML.”
Conference Coverage
Angelman syndrome treatment safe, well-tolerated, and effective in exploratory analyses
PHILADELPHIA – Experimental treatment may benefit adolescents and adults with Angelman syndrome.
Conference Coverage
Biomarkers in tears may help identify patients with Parkinson’s disease
PHILADELPHIA – Levels of oligomeric alpha synuclein are higher among patients with Parkinson’s disease than among...
Conference Coverage
Depressive symptoms are associated with stroke risk
PHILADELPHIA – Among older adults, elevated depressive symptoms are associated with a 75% greater risk of incident ischemic stroke.
Latest News
CSF and plasma biomarkers predict survival in sporadic Creutzfeldt-Jakob disease
An analysis suggests the possibility of using a minimally invasive biomarker to guide clinical care and improve clinical trial design.
From the Journals
Direct pharmacy dispensing of naloxone linked to drop in fatal overdoses
But emergency department visits related to opioids increased in new adopters of direct authority laws.
Conference Coverage
Brain volumes after TBI correlate with clinical features
PHILADELPHIA – Basal ganglia volume showed the highest variable importance with regards to classifying subjects who exhibited symptoms of...
Conference Coverage
Fremanezumab cut headache days in migraine patients vs. placebo
PHILADELPHIA – Patients studied had failed to get relief from other treatments.